STZ — Constellation Brands, Inc.

The Q1 FY27 adjusted EPS beat of $3.43, 34.7% operating margin, and Buy-rated analyst consensus (average target ~$165) are tempered by soft reported revenue, slowing beer depletions, tariff concerns, and weak price action. As of 2026-08-27, the stock has no momentum, but valuation and cash flow offer a floor.

The trend is margin-led improvement with modest organic growth, not a collapse. Reported revenue fell 3.3% YoY in Q1 FY27 to $2.43B, but the drop is attributable to wine/spirits divestitures; organic net sales rose 3%. Operating margin expanded to 34.7% from 31.7% in the year-ago quarter, and gross margin improved to 54.3% from 50.8%. GAAP EPS of $3.79 in Q1 FY27 compares to $2.90 a year earlier, and the big impairment-driven losses in Aug-2024 and Feb-2025 are not present in the latest quarters. FCF is steady at $1.83B TTM with $485M in the latest quarter. So the recent blip in reported revenue is a divestiture artifact; margins and cash generation are inflecting upward.

Cheap. As of 2026-08-27, trailing P/E is 12.5x and forward P/E is roughly 11.1x on FY27 consensus EPS of $11.80, versus a 5-year average P/E of 21.4x. P/S of 2.48x is well below the 5-year average of 3.99x, and TTM FCF yield is about 8%. The low multiple is partly deserved given D/E of 1.28, current ratio of 0.91, and volume softness, but the market is pricing a no-growth/stagnant business despite 52% gross margins, 32% operating margins, and 21% ROE.

At $131.43, the market is paying roughly 11x consensus forward EPS. That prices in meaningful deterioration. If management hits its $11.55 EPS guidance, the stock screens cheap even at a modest 13.5x multiple; consensus estimates and the $165 price target imply a re-rating to ~14x. If beer depletions keep falling and tariffs hit costs, the current multiple is just compensation for that risk. The playbook is to wait for volume-stabilization evidence (Q2 depletions) or a technical reclaim before treating the cheap multiple as a confirmed bargain.

As of 2026-08-27, RSI is 44.97, neutral rather than oversold, and price is 1.6% below the 20-day SMA, 2.4% below the 50-day, and 9.5% below the 200-day. The stock is range-bound/downtrending near the bottom of its 52-week range with no reversal signal. Entry timing is poor for momentum-based investors; value investors can start accumulating, but a reclaim of the 50-day SMA would improve the risk/reward.

• U.S. consumer wallet fatigue is pressuring beer depletions; STZ's high-end Mexican import portfolio is being watched for evidence that volume has bottomed.
• U.S.-Mexico trade policy/tariff risk on beer produced in Mexico could raise input and freight costs.
• Interest rates and sector rotation: a 3.1% dividend yield and defensive characteristics make STZ more attractive if rates fall, but staples have been out of favor.
• Moderating alcohol consumption and possible stricter regulation/labeling are slow-burn structural headwinds.
• Agricultural supply chain costs and the announced $100M supplier-investment program add a manageable cost/security variable.

• Q2 FY27 earnings in late September/early October 2026: core beer depletions and real-world consumer takeaway will set the tone.
• Barclays Global Consumer Conference on September 8, 2026, where incoming CEO Nicholas Fink and leadership may give mid-quarter demand/tariff commentary.
• Reaffirmation of FY27 EPS guidance at $11.55 (consensus $11.80) and any progress on paying down debt ($9.1B long-term debt).
• Easing of U.S.-Mexico tariff/trade tensions would reduce a major overhang.

• Beer volume could continue to decline if consumer spending weakens further, undercutting the bull case.
• Tariffs or trade restrictions on Mexican imports would pressure gross margin and freight costs.
• High leverage (D/E 1.28, current ratio 0.91) and only $97M cash leave limited balance-sheet cushion if conditions worsen.
• Leadership transition and wine/spirits divestiture execution create short-term uncertainty.

At $131.43, STZ is a fair business priced for bad news: $11.80 of forward EPS, $1.8B of annual FCF, a 3.1% dividend, and expanding margins, but also real volume, tariff, and balance-sheet risks. I would treat it as a patient value/income buy only if depletions stabilize; until then, it is a well-run staple at a reasonable price rather than a high-conviction must-own.

I applied a 13.5x forward P/E to FY27 consensus EPS of $11.80, which yields about $159, rounded to $160. The multiple is a clear discount to STZ's 5-year average P/E of 21.4x but a justified premium to the depressed ~11x current multiple given 52% gross margins, expanding operating margins, and an ~8% FCF yield; a ~20x TTM EV/FCF and ~3.0x forward sales cross-check land at roughly the same level.